UBS AM
VKTX icon

UBS AM’s Viking Therapeutics VKTX Stock Holding History

UBS AM’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.97M Sell
229,973
-23,921
-9% -$773K ﹤0.01% 1304
2026
Q1 		$8.26M Buy
253,894
+15,667
+7% +$504K ﹤0.01% 1302
2025
Q4 		$8.38M Sell
238,227
-5,539
-2% -$196K ﹤0.01% 1203
2025
Q3 		$6.41M Sell
243,766
-265,328
-52% -$7.92M ﹤0.01% 1254
2025
Q2 		$13.5M Buy
509,094
+39,066
+8% +$1.03M ﹤0.01% 1209
2025
Q1 		$11.4M Buy
470,028
+6,696
+1% +$212K ﹤0.01% 1166
2024
Q4 		$18.6M Sell
463,332
-8,912
-2% -$508K ﹤0.01% 982
2024
Q3 		$29.9M Sell
472,244
-7,150
-1% -$419K 0.01% 809
2024
Q2 		$25.4M Buy
479,394
+123,806
+35% +$8.12M 0.01% 786
2024
Q1 		$29.2M Sell
355,588
-119,525
-25% -$5.32M 0.01% 700
2023
Q4 		$8.84M Sell
475,113
-3,582
-0.7% -$46.8K ﹤0.01% 1036
2023
Q3 		$5.3M Buy
+478,695
New +$6.85M ﹤0.01% 1184
2022
Q2 		– Sell
-111,159
Closed -$333K – 2776
2022
Q1 		$333K Hold
111,159
– – ﹤0.01% 2567
2021
Q4 		$511K Hold
111,159
– – ﹤0.01% 2552
2021
Q3 		$698K Sell
111,159
-18,069
-14% -$112K ﹤0.01% 2340
2021
Q2 		$774K Buy
129,228
+28,988
+29% +$172K ﹤0.01% 2345
2021
Q1 		$634K Sell
100,240
-28,400
-22% -$200K ﹤0.01% 2300
2020
Q4 		$724K Buy
128,640
+56,500
+78% +$342K ﹤0.01% 2137
2020
Q3 		$420K Hold
72,140
– – ﹤0.01% 2207
2020
Q2 		$520K Sell
72,140
-14,523
-17% -$96.4K ﹤0.01% 2115
2020
Q1 		$406K Sell
86,663
-861
-1% -$5.29K ﹤0.01% 2052
2019
Q4 		$702K Buy
87,524
+6,242
+8% +$45.5K ﹤0.01% 2091
2019
Q3 		$559K Buy
81,282
+15,669
+24% +$116K ﹤0.01% 2238
2019
Q2 		$545K Buy
65,613
+18,354
+39% +$157K ﹤0.01% 2174
2019
Q1 		$470K Buy
47,259
+20,459
+76% +$171K ﹤0.01% 2130
2018
Q4 		$205K Buy
+26,800
New +$320K ﹤0.01% 2387

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS AM's VKTX Position: Q2 2026 in Review

UBS AM reduced its Viking Therapeutics (VKTX) stake by 9.4% in Q2 2026, selling an estimated $773K and leaving 229,973 shares worth $8.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

UBS AM first reported a position in VKTX in Q4 2018 and has held it in 26 quarters since. The position peaked at $29.9M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • UBS AM held 229,973 shares of Viking Therapeutics worth $8.97M as of Q2 2026.
  • UBS AM sold 23,921 Viking Therapeutics shares in Q2 2026, an estimated $773K.
  • Viking Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1304 holding.
  • UBS AM first reported a position in Viking Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • UBS AM's Viking Therapeutics position peaked at $29.9M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.